DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…

As SARS-CoV-2 continues to mutate we demonstrate the performance of 

One thing we can all agree on is that 2020 has been a strange year. But for us at Aptamer Group, it’s also been…

SARS-CoV-2 was first identified in November 2019 in Wuhan, China. Spreading quickly across the globe, COVID-19, the disease caused by SARS_CoV-2, was announced as a pandemic just four months…

The COVID-19 pandemic has presented significant challenges to the biopharmaceutical industry, requiring rapid discovery and development of affinity reagents targeting SARS-CoV-2 for research, diagnostics and therapeutics. The long development…

The world is currently gripped by the novel COVID-19 crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a highly pathogenic viral respiratory illness. It is…

25/11/2020 Aptamer Group Ltd, the developer of diagnostic and therapeutic aptamer reagents, is pleased to announce further progress in their collaboration with Integumen plc (AIM: SKIN) to develop Microtox PD,…

12/10/2020 Rachel Maskell, MP for York Central, visited one of the city’s most innovative businesses to see the progress it is making in supporting the COVID-19 pandemic, and the work…

28/09/2020 Collaboration to produce a rapid test for the COVID-19 coronavirus infection Aptamer Group, is pleased to announce that it has entered into a collaboration with Cytiva,…

09/07/2020 Collaboration to use aptamers in a device to detect SARS-CoV-2 in wastewater Aptamer Group, developers of Aptamer reagents, is pleased to announce that it has signed…